Attached files
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 22, 2009
--------------------------------
Lightlake Therapeutics Inc.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Nevada 333-139915 N/A
--------------------------------------------------------------------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
225-230 Queens Quay W, Toronto, ON M5J2Y7
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 416-841-5414
------------------------------
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
SECTION 4 - MATTERS RELATED TO ACCOUNTANTS AND FINANCIAL STATEMENTS
Item 4.01 Changes in Registrant's Certifying Accountant.
On August 17, 2009, Madrona Ventures Inc. (the "Company") now known as Lightlake
Therapeutics Inc. dismissed its auditing firm of Dale Matheson Carr-Hilton
Labonte LLP. On the same date, August 17, 2009, the accounting firm of PS
Stephenson & Co., P.C., CPA was engaged as the Company's new independent
auditing firm. The decision to change auditing firms was approved by the board
of directors of the Company.
Over the past two fiscal years our former auditor's report on our financial
statements did not contain an adverse opinion, a disclaimer of opinion, or was
qualified or modified as to uncertainty, audit scope or accounting principles.
However, our former auditor has raised doubt in the Company's ability to
continue as a going concern. In the two most recent fiscal years and the
subsequent interim period through the date of dismissal the Company did not have
any disagreements with our former auditing firm of Dale Matheson Carr-Hilton
Labonte LLP on any matter of accounting principles or practice, financial
statement disclosure, or auditing scope or procedure.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Lightlake Therapeutics Inc.
---------------------------
(Registrant)
Date 10/22/2009
---------- /s/ Seijin Ki
-------------
(Signature)
Director and Secretar
